SCHEMBL24875451

SCHEMBL24875451

CCOC(=O)C(Br)c1ccc(Br)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
MMP8 P22894 1/20 0.37
PIN1 Q13526 1/20 0.36
PTGS2 P35354 3/20 0.36
SLC6A4 P31645 1/20 0.36
SHBG P04278 1/20 0.36
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
PTGS1 P23219 1/20 0.35
MAPT P10636 3/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30192923 1.00 KDM4E (0.38) KDM4EMMP8PIN1PTGS2SLC6A4
SCHEMBL4295598 0.88 ALDH1A1 (0.42) KDM4EPTGS2SHBGAKR1C3AKR1C2
SCHEMBL28719127 0.86 MMP8 (0.44) KDM4EMMP8PIN1PTGS2SLC6A4
SCHEMBL24875595 0.85 PTGS2 (0.44) PTGS2AKR1C3AKR1C2PTGS1MAPT
SCHEMBL29234606 0.84 KIF11 (0.38) PTGS2SLC6A4MAPTKMT2AMEN1
SCHEMBL22230655 0.84 PTGS2 (0.36) KDM4EMMP8PIN1PTGS2SLC6A4
SCHEMBL24875709 0.84 AKR1C3 (0.46) MMP8AKR1C3AKR1C2PTGS1
SCHEMBL24875421 0.84 PTGS2 (0.38) KDM4EMMP8PIN1PTGS2SLC6A4
SCHEMBL8593582 0.82 PTGS2 (0.37) KDM4EMMP8PIN1PTGS2SLC6A4
SCHEMBL24875778 0.82 AKR1C3 (0.39) KDM4EMMP8PIN1PTGS2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. 2024-11-14 US disclosed
EP-4366829-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2024-05-15 EP disclosed
CN-117957212-A IL-17A modulators based on phenylacetamide and uses thereof 戴斯阿尔法公司 2024-04-30 CN disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF IL17A, IL1A, IL2 KDM4E 1263/4885MMP8 324/4885PIN1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.